COCP (Cocrystal Pharma) EBIT per Share : $-1.99 (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma EBIT per Share?

Cocrystal Pharma's EBIT per Share for the three months ended in Sep. 2024 was $-0.50. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.99.

During the past 3 years, the average EBIT per Share Growth Rate was -1.70% per year. During the past 5 years, the average EBIT per Share Growth Rate was 0.20% per year. During the past 10 years, the average EBIT per Share Growth Rate was 26.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cocrystal Pharma's EBIT per Share or its related term are showing as below:

COCP' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -268.5 Med: 5.35 Max: 74.8
Current: -1.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cocrystal Pharma was 74.80% per year. The lowest was -268.50% per year. And the median was 5.35% per year.

COCP's 3-Year EBIT Growth Rate is ranked worse than
56.01% of 1248 companies
in the Biotechnology industry
Industry Median: 2.8 vs COCP: -1.70

Cocrystal Pharma's EBIT for the three months ended in Sep. 2024 was $-5.04 Mil.

Cocrystal Pharma EBIT per Share Historical Data

The historical data trend for Cocrystal Pharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma EBIT per Share Chart

Cocrystal Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-18.14

-2.10

-1.93

-2.23

-2.19

Cocrystal Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial															-0.60	-0.55	-0.41	-0.54	-0.50

Cocrystal Pharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cocrystal Pharma's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-21.159	/	9.651
=	-2.19

Cocrystal Pharma's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.042	/	10.174
=	-0.50

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.99

Cocrystal Pharma (NAS:COCP) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cocrystal Pharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cocrystal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

8CC:Germany

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Executives

Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al	director, 10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi	director, 10 percent owner	1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin	officer: Interim CFO	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale	officer: INTERIM CFO	1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers	officer: CHIEF MEDICAL OFFICER	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott	officer: GENERAL COUNSEL AND SECRETARY	1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler	director	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block	director
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027